Danaher Corporation
Every calculator, already run for DHR
Open the full toolkit →You have the numbers on DHR. Get the argument.
A written report on which of these readings actually decide the outcome for Danaher Corporation, what has to stay true for the price to work, and the specific thing that would break it. The first one is free.
Key market data
Analyst consensus
26 analysts covering DHRAnalyst Price Target Disagreement for Danaher Corporation
Wall Street's bull case implies +49% from the current price; the bear case implies -6%. A 55% spread signals high analyst disagreement — run your own DCF to anchor on fundamentals rather than street consensus.
Ownership & short interest
Insider Trading Activity for DHR
| Insider | Role | Type | Shares | Price | Value | Date | Filing |
|---|---|---|---|---|---|---|---|
About Danaher Corporation
Danaher Corporation designs, manufactures, and markets professional, medical, research, and industrial products and services in the United States, China, and internationally. The company operates through Biotechnology, Life Sciences, and Diagnostics segments. The Biotechnology segment provides technologies, consumables, services, and solutions that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, and aseptic fill finish; single-use hardware, consumables, and services, such as the design and…
DHR — frequently asked
Is DHR a buy right now?
Wall Street's consensus rating on Danaher Corporation is Strong Buy across 26 analysts, with a mean price target of $229.09 (+10% vs. the current $207.66). Ratings are a starting point — run the DCF and check the financial-health readings above before deciding.
Is DHR overvalued?
DHR trades at 37.0x trailing earnings, against a DCF fair value of $161 per share. The current price implies 9% annual free-cash-flow growth for a decade. Open the DCF or reverse-DCF tool to change the assumptions and see the range.
When is DHR's next earnings date?
Danaher Corporation is next scheduled to report earnings around Oct 20, 2026. A full DHR research report from Basis Report covers the setup into that print — estimates, the beat/miss record, and what would move the thesis.
What is the analyst price target disagreement for Danaher Corporation?
Analysts covering Danaher Corporation (DHR) range from a bear-case target of $195.00 to a bull-case high of $310.00, with a mean consensus target of $229.09 across 23 analysts. The spread of $115.00 (55% of the current price) indicates high disagreement on the outlook. Run the DCF calculator to build your own estimate independent of street consensus.
Compare Danaher Corporation against related stocks
Explore additional stock overview pages and jump directly into full report generation for each symbol.
Sector peers
Most-followed names in the same sector.
Nearby tickers
Additional public equities from our tracked universe.
Market leaders
Large-cap symbols investors frequently compare.
Investor Guides For Danaher Corporation
Start with the evergreen guides that matter most for Healthcare, then move back into the ticker page when you want to pressure-test the framework on a live name.
Generate your full DHR research report
DCF model, five-year financials, moat assessment, a BUY/HOLD/SELL rating, and the risks that matter — on Danaher Corporation, in minutes. 3 free reports included with every account — no credit card required.